Cantargia AB (publ) (STO:CANTA)
Sweden · Delayed Price · Currency is SEK | Market Cap | 731.42M +83.0% |
| Revenue (ttm) | 317.21M |
| Net Income | 160.93M |
| EPS | 0.63 |
| Shares Out | 248.61M |
| PE Ratio | 4.66 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,022,643 |
| Average Volume | 1,561,916 |
| Open | 3.208 |
| Previous Close | 3.180 |
| Day's Range | 2.750 - 3.272 |
| 52-Week Range | 1.000 - 6.590 |
| Beta | 1.65 |
| RSI | 26.23 |
| Earnings Date | May 19, 2026 |
About Cantargia AB
Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an monoclonal antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in phase 1 clinical trial for the treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It al... [Read more]
Financial Performance
Financial StatementsNews
Cantargia AB (FRA:7V3) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial ...
Cantargia AB (FRA:7V3) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
Cantargia AB Earnings Call Transcript: Q1 2026
Refined focus on PDAC and hematology leverages nadunolimab's potential amid evolving treatment landscapes. Q1 2026 saw disciplined spending, a SEK 33M loss, and a cash runway into 2028, with strong early MDS data and ongoing pipeline expansion.
Cantargia AB Quarterly report: Q1 2026
Cantargia AB has published its Q1 2026 quarterly earnings report on May 19, 2026.
Cantargia AB Slides: Corporate presentation
Cantargia AB has posted slides in relation to its latest quarterly earnings report, which was published on May 19, 2026.
Cantargia AB (OSTO:CANTA) Q1 2026 Earnings Report Preview: What To Look For
Cantargia AB (OSTO:CANTA) Q1 2026 Earnings Report Preview: What To Look For
Cantargia AB (FRA:7V3) Q4 2025 Earnings Call Highlights: A Year of First-Time Profitability ...
Cantargia AB (FRA:7V3) Q4 2025 Earnings Call Highlights: A Year of First-Time Profitability Amidst Ongoing Challenges
Q4 2025 Cantargia AB Earnings Call Transcript
Q4 2025 Cantargia AB Earnings Call Transcript
Cantargia AB Earnings Call Transcript: Q4 2025
Advanced nadunolimab to pivotal trial readiness in PDAC, reported strong financials with first-ever annual profit, and secured a robust cash runway into 2028. Investor interest in PDAC is rising, and key milestones are targeted for 2026.
Cantargia AB Quarterly report: Q4 2025
Cantargia AB has published its Q4 2025 quarterly earnings report on February 20, 2026.
Cantargia AB Slides: Q4 2025
Cantargia AB has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 20, 2026.
Cantargia AB Annual report: Q4 2025
Cantargia AB has published its Q4 2025 annual report on February 20, 2026.
Cantargia AB (FRA:7V3) Q3 2025 Earnings Call Highlights: First-Ever Profits and Promising ...
Cantargia AB (FRA:7V3) Q3 2025 Earnings Call Highlights: First-Ever Profits and Promising Cancer Treatment Results
Q3 2025 Cantargia AB Earnings Call Transcript
Q3 2025 Cantargia AB Earnings Call Transcript
Cantargia AB Earnings Call Transcript: Q3 2025
Q3 2025 saw a major financial boost from the Otsuka deal, resulting in first-ever reported profits and a strengthened cash position. Nadunolimab in PDAC remains the strategic focus, with a pivotal trial planned for mid-2026, while new pipeline assets advance in preclinical stages.
Cantargia AB Quarterly report: Q3 2025
Cantargia AB has published its Q3 2025 quarterly earnings report on November 19, 2025.
Cantargia AB Slides: Q3 2025
Cantargia AB has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 19, 2025.
Cantargia AB Transcript: Life Science Summit 2025
Nadunolimab, a pivotal-ready antibody for PDAC, showed improved survival in patients with high IL1RAP levels and received FDA fast-track status. Financial flexibility from a major partnership supports further development, with a pivotal trial and biomarker-driven strategy planned.
Cantargia AB Transcript: Investing in Life Science 2025
Nadunolimab advances as a lead IL-1RAP antibody in cancer, with FDA fast-track status and a focus on high IL-1RAP patients. A major Otsuka deal provides financial flexibility, while ongoing trials and a new CEO's strategic focus aim to maximize the asset's potential.
Cantargia AB Earnings Call Transcript: Q2 2025
Otsuka acquired CAN10 for $33M upfront plus up to $580M in milestones, with deal closing in Q3 2025. Operating expenses fell 10% year-over-year, and a new CEO, Dr. Hilde Steineger, was appointed. Nadunolimab received FDA fast-track in PDAC, and the company expects improved financial stability.
Cantargia AB Quarterly report: Q2 2025
Cantargia AB has published its Q2 2025 quarterly earnings report on August 21, 2025.
Cantargia AB Slides: Q2 2025
Cantargia AB has posted slides in relation to its Q2 2025 quarterly earnings report, which was published on August 21, 2025.
Cantargia AB Earnings Call Transcript: Q1 2025
Strong clinical progress with CANTEN and nadunolimab, including phase 1 completion and new indications, drove higher R&D costs and operating losses. Cash runway extends into Q4 2025, but additional funding is needed amid challenging biotech market conditions.
Cantargia AB Quarterly report: Q1 2025
Cantargia AB has published its Q1 2025 quarterly earnings report on May 13, 2025.
Cantargia AB Slides: Q1 2025
Cantargia AB has posted slides in relation to its Q1 2025 quarterly earnings report, which was published on May 13, 2025.
Cantargia AB Earnings Call Transcript: Q4 2024
Leadership transition brings focus on value creation and transactions for lead assets. Operating expenses fell 42% year-over-year, with a strengthened cash position post-rights issue. Multiple clinical milestones and potential partnerships are expected in 2024–2025.